These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 16340473)

  • 1. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
    Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
    J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
    Sreenivasan S; Dasegowda V
    J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
    Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH
    AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
    Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
    Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
    Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
    Kumarasamy N; Venkatesh KK; Devaleenol B; Saghayam S; Manohar D; Poongulali S; Yepthomi T; Ambrose P; Solomon S; Mayer KH
    Int J Infect Dis; 2009 Nov; 13(6):e360-4. PubMed ID: 19328734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
    Birlie B; Braekers R; Awoke T; Kasim A; Shkedy Z
    BMC Infect Dis; 2017 Jun; 17(1):453. PubMed ID: 28655306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
    Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
    AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
    Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
    Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
    Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
    Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.
    Li T; Dai Y; Kuang J; Jiang J; Han Y; Qiu Z; Xie J; Zuo L; Li Y
    PLoS One; 2008; 3(12):e3918. PubMed ID: 19081791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
    Zhou J; Paton NI; Ditangco R; Chen YM; Kamarulzaman A; Kumarasamy N; Lee CK; Li PC; Merati TP; Phanuphak P; Pujari S; Vibhagool A; Zhang F; Chuah J; Frost KR; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):8-16. PubMed ID: 17305926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised control trial of structured interrupted generic antiretroviral therapy versus continuous therapy in HIV-infected individuals in Southern India.
    Kumarasamy N; Flanigan TP; Vallabhaneni S; Cecelia AJ; Christybai P; Balakrishnan P; Yepthomi T; Solomon S; Carpenter CC; Mayer KH
    AIDS Care; 2007 Apr; 19(4):507-13. PubMed ID: 17453591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.